Glucose for the Heart

104. McDonald T, Mac Leod D. Metabolism and the electrical activity of ventricular muscle. J Physiol (Lond). 1973;229:559–582. 105. Scheuer J, Stezoski SW. Protective role of increased myocardial glycogen stores in cardiac anoxia in the rat. Circ Res. 1970;27:835–849. 106. Lagerstrom CF, Walker WE, Taegtmeyer H. Failure of glycogen depletion to improve left ventricular function of the rabbit heart after hypothermic ischemic arrest. Circ Res. 1988;63:81–86. 107. Schneider CA, Taegtmeyer H. Fasting in vivo delays myocardial cell damage after brief periods of ischemia in the isolated working rat heart. Circ Res. 1991;68:1045–1050. Depre et al February 2, 1999 587 by gest on A ril 6, 2017 http://ciajournals.org/ D ow nladed from 108. Doenst T, Guthrie PH, Chemnitius JM, Zech R, Taegtmeyer H. Fasting, lactate, and insulin improve ischemia tolerance: a comparison with ischemic preconditioning. Am J Physiol. 1996;270:H1607–H1615. 109. Depre C, Hue L. Inhibition of glycogenolysis by a glucose analogue in the working rat heart. J Mol Cell Cardiol. 1997;29:2253–2259. 110. Runnman EM, Lamp ST, Weiss JN. Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux.J Clin Invest. 1990;86:1222–1233. 111. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart?: a controversy resolved.Circ Res. 1996;78:482–491. 112. Vanoverschelde JL, Wijns W, Borgers M, Heyndrickx G, Depre C, Flameng W, Melin J. Chronic myocardial hibernation: from bedside to bench.Circulation. 1997;95:1961–1971. 113. Borgers M, Thoné F, Wouters L, Ausma J, Shivalkar B, Flameng W. Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis. Cardiovasc Pathol. 1993;2:237–245. 114. Elsasser A, Schleper M, Klovekorn WP, Cai WP, Zimmermann R, Muller KD, Strasser R, Kostin S, Gagel C, Munkel B, Schaper W, Schaper J. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation. 1997;96:2920–2931. 115. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki LM, Ruotsalainen U, Haaparenta M, Solin O, Hartiala J, Harkonen R, Knuuti MJ. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996;93:1658–1666. 116. Depre C, Vanoverschelde JL, Gerber B, Borgers M, Melin J, Dion R. Correlation of functional recovery with myocardial blood flow, glucose uptake, and morphologic features in patients with chronic left ventricular ischemic dysfunction undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1997;113:371–378. 117. Thompson EW, Marino TA, Uboh CE, Kent RL, Cooper G. Atrophy reversal and cardiocyte redifferentiation in reloaded cat myocardium. Circ Res. 1984;54:367–377. 118. Depre C, Havaux X, Dion R, Vanoverschelde JL. Morphologic alterations of myocardium under left ventricular assistance. J Thorac Cardiovasc Surg. 1998;115:478–479. 119. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis.Am J Physiol. 1986;251:H1306–H1315. 120. Weiss RG, de Albuquerque CP, Vandegaer K, Chacko VP, Gerstenblith G. Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioned rat hearts. Circ Res. 1996;79:435–446. 121. Wolfe CL, Sievers RE, Visseren FLJ, Donnelly TJ. Loss of myocardial protection after preconditioning correlates with the time-course of glycogen recovery within the preconditioned segment. Circulation. 1990;66:913–931. 122. Kida M, Fujiwara H, Ishida M, Keuwon C, Ohura M, Miura I, Yabunclin Y. Ischemic preconditioning preserves creatine phosphate and intracellular pH.Circulation. 1991;84:2495–2503. 123. Liedtke AJ, Demaison L, Nellis SH. Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts. Am J Physiol . 1988; 255:169–176. 124. Gorge G, Chatelain P, Schaper J, Lerch R. Effect of increasing degrees of ischemic injury on myocardial oxidative metabolism early after reperfusion in isolated rat hearts. Circ Res. 1991;68:1681–1692. 125. Benzi RH, Lerch R. Dissociation between contractile function and oxidative metabolism in postischemic myocardium. Circ Res. 1992;71: 567–576. 126. Liu B, Alaoui-Talibi Z, Clanachan AS, Schultz R, Lopaschuk GD. Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol . 1996;270:H72–H80. 127. Mallet RT, Hartman DA, Bünger R. Glucose requirement for postischemic recovery of perfused working heart. Eur J Biochem. 1990;188:481–493. 128. Jeremy RW, Koretsune Y, Marban E, Becker LC. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res. 1992;70:1180–1190. 129. Tamm C, Benzi RH, Papageorgiou I, Tardy I, Lerch R. Substrate competition in postischemic myocardium: effect of substrate availability during reperfusion on metabolic and contractile recovery in isolated rat hearts.Circ Res. 1994;75:1103–1112. 130. du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion.Circ Res. 1992;70:960–967. 131. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol. 1990;259:H1079–H1085. 132. Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68: 1250–1258. 133. Tani M. Mechanism of Ca 11 overload in reperfused ischemic myocardium. Annu Rev Physiol. 1990;52:543–559. 134. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5 9-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513–17520. 135. Kudo N, Gillespie JG, Kung L, Witters, LA, Schulz R, Clanachan AS, Lopaschuk GD. Characterization of 5 9AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1996; 1301:67–75. 136. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart.Eur J Biochem.1989;180:221–233. 137. De Leiris J, Lubbe WF, Opie LH. Effects of free fatty acid and glucose on enzyme release in experimental myocardial infarction. Nature. 1975; 153:746–747. 138. Sodi-Pallares D, Testelli MR, Fishleder BL. Effects of intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol. 1962;9:166–181. 139. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, Covell JW, Braunwald E. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion.Circulation. 1972;45:1160–1175. 140. Rogers WJ, Stanley AW, Breing JB, Prather JW, McDaniel HG, Moraski RE, Mantle JA, Russell RO, Rackley CE. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulinpotassium infusion. Am Heart J. 1976;92:441–454. 141. Whitlow PL, Rogers WJ, Smith LR, McDaniel HG, Papapietro SE, Mantle JA, Logic JR, Russell RO, Rackley CE. Enhancement of left ventricular function by glucose-insulin-potassium infusion in acute myocardial infarction.Am J Cardiol. 1982;49:811–820. 142. Satler LF, Green CE, Kent KM, Pallas RS, Pearle DL, Rackley CE. Metabolic support during coronary reperfusion. Am Heart J. 1987;114: 54–58. 143. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.J Am Coll Cardiol. 1995;26:57–65. 144. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152–1156. 145. Schaefer S, Prussel E, Carr LJ. Requirement of glycolytic substrate for metabolic recovery during moderate low flow ischemia. J Mol Cell Cardiol. 1995;27:2167–2176. 146. Taegtmeyer H, Villalobos DH. Metabolic support for the postischaemic heart.Lancet. 1995;345:1552–1555. 147. Lazar HL. Enhanced preservation of acutely ischemic myocardium using glucose-insulin-potassium solutions. J Card Surg. 1984;9:474–478. 148. Gradinak S, Coleman GM, Taegtmeyer H, Sweeney F, Frazier H. Improved cardiac function with glucose-insulin-potassium after coronary bypass surgery. Ann Thorac Surg. 1989;48:484–489. 149. Taegtmeyer H, Goodwin GW, Doenst T, Frazier OH. Substrate metabolism as a determinant for postischemic functional recovery of the heart. Am J Cardiol. 1997;80:3A–10A. 150. Lazar HL, Philippides G, Fitzgerald C, Lancaster D, Sherwin RI, Apstein CS. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg . 1997;113:354–362. 151. O’Rourke B, Ramza BM, Marban E. Oscillations of membrane current and excitability driven by metabolic oscillations in heart cells. Science. 1994;265:962–966. 152. Lolley DM, Ray JF, Myers WO, Sauter RD, Tewksbury DA. Importance of preoperative myocardial glycogen levels in human cardiac preservation.Cardiovasc Surg. 1979;78:678–687.

T he homeostasis of plasma glucose levels is essential for survival of the mammalian organism.Since blood glucose concentration is maintained within a narrow range, glucose is a most reliable substrate for energy production in the heart.The importance of glucose metabolism via glycolysis is well appreciated in ischemic and hypertrophied heart muscle, [1][2][3][4] but aerobic glucose metabolism for support of normal contractile function has received less attention, mainly because of the well-known fact that fatty acids are normally the predominant fuel for cardiac energy production. 2,5,6We have drawn attention to the heart as a true "omnivore," ie, an organ that functions best when it oxidizes different substrates simultaneously. 7In light of this concept, we wish to reexamine myocardial glucose metabolism and its relevance to the human heart.In recent years, the tools of molecular and cellular biology have provided new insight into the mechanisms of glucose transport and phosphorylation.Glycogen metabolism has come into greater focus.The regulation of glycolysis is more accurately defined, and the effects of second messengers on myocardial glucose utilization are better known.In view of this background, 2 wellknown clinical concepts of myocardial glucose metabolism require critical reevaluation: (1) the diagnostic concept of metabolic imaging with PET and the glucose tracer analogue 18 F-2-deoxy-2-fluoro-D-glucose (FDG) and (2) the therapeutic concept of metabolic support for the postischemic heart with glucose, insulin, and K ϩ (GIK).

Regulation of Glucose Metabolism in Normoxic Heart
The simple sugar D-glucose is the most abundant organic molecule in nature.Glucose for the heart is derived either from the bloodstream or from intracellular stores of glycogen (Figure 1).The transport of glucose into the cardiomyocyte occurs along a steep concentration gradient and is regulated by specific transporters.Intracellular glucose is rapidly phosphorylated and becomes a substrate for the glycolytic pathway, glycogen synthesis, and ribose synthesis.After entering the glycolytic pathway, glucose is ultimately broken down to pyruvate (Figure 1), which, in turn, is a substrate for further metabolic pathways.Glucose uptake, defined as glucose transport and phosphorylation, is measured as the product of glucose extraction (percentage)ϫarterial concentration of glucoseϫflow.Measurements of net glucose uptake and lactate release by the arteriovenous differences have been extensively used in humans to assess glucose metabolism, but measurements in vivo are not as precise as in isolated hearts.In the latter, glucose metabolism can be directly assessed by labeled tracers and analogues.For instance, glucose uptake may be measured by the detrition rate of [2-3 H]glucose, and glycolytic flux may be measured by the detrition rate of [3-3 H]glucose or [5-3 H]glucose.Similarly, glucose oxidation may be measured by the release of 14 CO 2 from [ 14 C]glucose.Glycogen may also be labeled with the same tracers.Dual-or triple-labeling techniques allow precise measurement of the relative amounts of glucose derived from glycogen compared with glucose derived from extracellular sources. 8The quantitative determination of glucose uptake by the glucose tracer analogue 2-deoxyglucose or FDG is based on the assumption that, unlike glucose 6-phosphate, 2-deoxyglucose 6-phosphate and FDG 6-phosphate are irreversibly trapped in the tissue and are neither subject to further metabolism nor subject to dephosphorylation.The 3-compartment model of Sokoloff et al 9 and the graphic analysis of Patlak et al 10 are commonly used to quantify the rates of myocardial glucose uptake from dynamic measurements of radioactivity in a region of interest. 11Under steady-state conditions, the accumulation of tracers is linear and follows zero-order kinetics. 12Since the affinity of glucose transport is higher and that of hexokinase is lower for deoxyglucose than for glucose, Sokoloff et al introduced a lumped constant (LC) to calculate rates of glucose uptake from tissue activity in the brain.However, derivation of this formula for tracer kinetic analysis of glucose uptake in the heart 13 is flawed by a trivial solution, 14 and LC decreases significantly with insulin or after addition of another substrate together with glucose. 15Combining upper and lower limits for LC with the ratio between unidirectional and steady-state FDG uptake rates allows the prediction of individual LCs and, hence, the quantification of myocardial glucose uptake by a simple tracer kinetic model. 16

Glucose Transport
The transporters regulating the uptake of glucose belong to the GLUT family [17][18][19] and constitute a system of stereospecific and saturable transport/countertransport.The isoform that is predominantly expressed at the surface of adult cardiomyocytes is GLUT 4, the insulin-sensitive transporter also found in adipose tissue. 17In addition, the cardiomyocyte expresses the GLUT 1 transporter, which is presumably independent of insulin action and predominant in fetal myocardium. 18Both transporters have a K m for glucose (ie, the concentration of glucose at which the rate of transport is half-maximal) that is in the range of plasma glucose concentrations under fasting conditions. 20The normal heart also expresses a low amount of GLUT 3, which has a K m below the normal plasma glucose concentration. 21Stimulation of glucose transport is exerted by a recruitment of transporters from intracellular stores to the plasma membrane, [17][18][19] resulting in an increased maximal velocity of transport.

Hexokinase
Glucose phosphorylation by hexokinase is the first regulatory step that commits glucose to further metabolism (Figure 1).Two different isozymes of hexokinase are present in the heart, hexokinases I and II. 22Hexokinase I is predominant in the fetal and newborn heart, whereas the insulin-regulated hexokinase II is predominant in the adult heart.The reasons for this genetic shift are not known.Hexokinase is present in the cytosolic fraction of the cell but also binds to the outer mitochondrial membrane. 23Binding lowers the K m for glucose and increases hexokinase activity, 24 although the K m for 2-deoxyglucose remains nearly 10-fold higher than that for glucose. 24This attachment also suppresses inhibition of hexokinase by glucose 6-phosphate. 23Insulin shifts the control strength of glucose uptake from glucose transport to phosphorylation.Control strength is defined as the ratio of the change in enzyme activity on the change in the pathway flux. 25

Glycogen Metabolism
Although the bulk of glucose 6-phosphate enters the glycolytic pathway (Figure 1), glucose 6-phosphate is also a substrate for glycogen synthesis.The dynamics of glycogen turnover have recently been investigated, and cycling of glucose moieties in and out of glycogen has been proposed as a control site for myocardial glucose metabolism. 7Glycogen occupies about 2% of the cell volume of the adult and 30% of the cell volume of the fetal and newborn cardiomyocyte. 26nlike liver and skeletal muscle, heart muscle increases its glycogen content with fasting. 27This observation is consistent with the general principle that fatty acids, the predominant fuel for the heart during fasting, inhibit glycolysis more than glucose uptake, thereby rerouting glucose toward glycogen synthesis.Glycogen stores are also increased by insulin, from the simultaneous stimulation of glucose transport and glycogen synthase activity. 28Net glycogen synthesis also occurs when lactate is the predominant fuel for the heart. 29,30 variable amount of exogenous glucose cycles through glycogen before entering the glycolytic pathway.The cycling of glucose through the glycogen pool is substrate dependent.In isolated working rat heart perfused with glucose as sole substrate, a small part of extracellular glucose taken up by the cell is incorporated into glycogen before entering the glycolytic pathway, 31 whereas this incorporation rate is significantly greater in vivo, when hormones and competing substrates are present. 32At the other end of the spectrum, glycogen is rapidly broken down when glycogen phosphorylase is stimulated by epinephrine or glucagon. 31Glycogen phosphorylase is the main regulator of glycogenolysis and one of the best-studied enzymes.It is activated by phosphorylation, either by cAMP-dependent protein kinase or by Ca 2ϩ -activated phosphorylase kinase. 33Glycogen breakdown is also rapidly stimulated during sudden increases of heart work. 34,35Glucosyl moieties coming from glycogen breakdown are preferentially oxidized rather than converted to lactate. 34As a result, there is a dichotomy between glucosyl units coming from extracellular glucose, which are metabolized into lactate, and glucosyl units coming from glycogen, which are oxidized.After the addition of epinephrine (in the presence of physiological concentrations of fatty acids), the extra energy requirements are initially met by glycogenolysis and then by a sustained increase in the rate of glucose oxidation. 36,37

6-Phosphofructo-1-Kinase
The first regulatory site that commits glucose to the glycolytic pathway is at the level of 6-phosphofructo-1-kinase (PFK-1), catalyzing the phosphorylation of fructose 6-phosphate to fructose 1,6-bisphosphate (Figure 1).Because of a complex allosteric regulation, 38 conversion of fructose 6-phosphate into fructose 1,6-diphosphate is a rate-limiting step of glycolysis.ATP, citrate, and protons are negative allosteric effectors, 38,39 whereas AMP and fructose 2,6diphosphate are positive effectors. 40,41Fructose 2,6diphosphate is the main activator of PFK-1 in normoxic heart. 42][44] GAPDH catalyzes the transformation, by oxidation and phosphorylation, of glyceraldehyde 3-phosphate into 1,3diphosphoglycerate.As is the case with most dehydrogenases, GAPDH is inhibited by high concentrations of NADH and protons. 45yruvate kinase catalyzes the transformation of phospho(enol)pyruvate into pyruvate.Pyruvate kinase, which constitutes an irreversible step of glycolysis in heart muscle, may increase glycolytic flux, because it is stimulated by fructose 1,6-diphosphate, the product of PFK-1. 46PFK-1 thus synchronizes several glycolytic reactions, allowing an acceleration of the glycolytic pathway without accumulation of the glycolytic intermediates.

Fate of Pyruvate
Pyruvate enters the mitochondria via a monocarboxylate carrier. 47In the mitochondrial matrix, pyruvate becomes an intermediate at a branch point for several metabolic pathways (Figure 2).Most of pyruvate produced either from glycolysis or from exogenous lactate is oxidized to acetyl coenzyme A (acetyl-CoA) by the pyruvate dehydrogenase complex (PDC) and fed into the Krebs cycle.Pyruvate can also replenish Krebs cycle intermediates through its transformation into oxaloacetate by pyruvate carboxylase or malic enzyme. 48 -50his mechanism of replenishment in a metabolic cycle is also termed anaplerosis.Oxidative decarboxylation of pyruvate to acetyl-CoA by the PDC commits pyruvate to oxidation.The PDC is a mitochondrial multienzyme complex that is regulated by its substrates and products and by phosphorylation/ dephosphorylation (Figure 3).Pyruvate dehydrogenase (PDH) kinase, which inhibits the PDC, is stimulated by acetyl-CoA and NADH (produced mainly by fatty acid oxidation) and inhibited by pyruvate (produced from glucose and lactate), whereas PDH phosphatase, which activates the PDC, is mainly stimulated by Ca 2ϩ . 51,52The activation of the PDC observed in working hearts submitted to increased workload or perfused with epinephrine appears to be the result of increased mitochondrial Ca 2ϩ entry. 52

Long-Chain Fatty Acid Metabolism
The inhibition of glucose oxidation by fatty acids is a well-known phenomenon of mammalian metabolism.Its mechanisms were defined in the isolated perfused heart, and the results gave rise to the formulation of the "glucose-fatty acid cycle." 5 Glucose may also inhibit fatty acid oxidation, as follows.The transfer of the fatty acyl moieties into mitochondria, where ␤-oxidation occurs, is catalyzed by carnitine palmitoyltransferases (CPT-1 and CPT-2).The rate of fatty acid oxidation is controlled by their rate of transfer into the mitochondria through CPT-1 (Figure 4). 6This latter step is inhibited by malonyl-CoA, 53 formed from acetyl-CoA by acetyl-CoA carboxylase (ACC). 54,55Conditions that increase the production of acetyl-CoA from pyruvate (as an increased concentration of glucose or lactate or the addition of insulin) stimulate the production of malonyl-CoA and thereby inhibit the ␤-oxidation.Such a mechanism leads to the suppression of fatty acid oxidation by glucose or lactate and is reinforced by the fact that high plasma levels of glucose and insulin decrease the concentration of circulating fatty acids.

The Krebs Cycle
The Krebs cycle is perhaps the best example for the paradigm of efficient energy transfer through metabolic cycles, which includes the recycling of CO 2 and H 2 O. Without the recycling of H 2 O, ATP production by the Krebs cycle would be 60%  less than with recycling (6 versus 15 moles of ATP per mole pyruvate oxidized). 7Under normoxic conditions, pyruvate is not only decarboxylated but also carboxylated to oxaloacetate and malate (Figure 2).This mechanism allows both a "refeeding" of Krebs cycle intermediates and a recycling of CO 2 produced from the action of dehydrogenases. 48Fixation of CO 2 is particularly important during prolonged oxidation of fatty acids and ketone bodies, which can "unspan" the Krebs cycle by the sequestration of coenzyme A. 56 The potential contribution of substrates to anaplerosis has given rise to the distinction between glucose and lactate, which produce both acetyl-CoA and oxaloacetate, and fatty acids or ketone bodies, which produce only acetyl-CoA.The need for anaplerosis may explain why glucose uptake is never completely inhibited in hearts perfused with fatty acids.

Malate-Aspartate Shuttle
This shuttle, first discovered in the liver, is also of major importance for the heart. 57Several of the intermediates presented in Figure 4 participate in the transfer of reducing equivalents from cytosol to mitochondrion.The malateaspartate shuttle operates through 2 carriers, the dicarboxylate carrier, which exchanges malate and 2-oxoglutarate, and the aspartate/glutamate shuttle, which exchanges these 2 amino acids.The net effect of the malate-aspartate shuttle is the transfer of hydrogen ions from the cytosol (where they are produced) into the mitochondrion (where they are consumed by the electron transport chain for oxidative phosphorylation).These carriers thus preserve the ionic balance between the cytosol and mitochondria.Such a mechanism may be of particular importance during postischemic reperfusion, when protons produced by ATP breakdown need to be carried into the mitochondria (see below).

Substrate Supply
Quantity and quality of substrate supply to the heart are determined by the dietary state and physical activity of the body as a whole.Long-chain fatty acids are the major substrates for the heart.With fasting, fatty acids and triglycerides are released from the adipose tissue and enter the circulation.Fatty acids are taken up by the cardiac cell to be degraded to acetyl-CoA.Oxidation of acetyl-CoA begins with the formation of citrate, which is the first intermediate of the citric acid cycle.By an allosteric feedback mechanism, citrate inhibits glycolysis at the PFK-1 step. 39Inhibition of glucose metabolism by fatty acid oxidation was first observed in isolated perfused heart muscle 5 and also occurs in vivo. 58s already stated, fatty acids inhibit glucose oxidation more than glycolysis and glycolysis more than glucose uptake. 44,59lucose becomes the main substrate for oxidative metabolism of the heart when fatty acid levels are low and when the concentrations of glucose and insulin are high, as in the postprandial state. 7We have already mentioned that glucose decreases rates of long-chain fatty acid oxidation, 60 most likely at the level of CPT-1 through the production of malonyl-CoA by ACC. 54,55Other substrates are lactate and ketone bodies.The uptake and utilization of these substrates by the heart is a function of their blood concentration. 7sotopic studies in vivo have shown that the heart takes up lactate in spite of net lactate release. 61There are 2 separate nonexchanging pools of lactate in the isolated glucoseperfused rat heart. 62Lactate contributes significantly to the supply of carbons for the tricarboxylate cycle and may replace all other substrates (including glucose), especially after exercise. 63Ketone bodies are produced from the catabolism of fatty acids in the liver, and their plasma concentra- tion rises mainly with starvation, in the last trimester of pregnancy, and in diabetic ketoacidosis. 64Both lactate and ketone bodies inhibit glycolytic flux through elevating the cytosolic levels of citrate and NADH, by the same mechanism as for fatty acids. 29,44Moreover, ketone bodies require CoA-SH moieties to be activated.Because CoA-SH is also a cosubstrate for the Krebs cycle enzyme 2-oxoglutarate dehydrogenase, flux through the cycle is inhibited, and the heart cannot sustain its contractile activity when oxidizing ketone bodies only. 64Because glucose or pyruvate restore normal function, this observation of reversible contractile dysfunction due to the depletion and replenishment of the Krebs cycle caused us to propose the concept of shared substrate supply. 7

Hormonal Milieu
The hormonal regulation of glucose metabolism involves catecholamines, insulin, glucagon, thyroid hormones, and acetylcholine.It also includes paracrine molecules, such as bradykinin, or cytokines, such as tumor necrosis factor-␣.Epinephrine increases glycogen breakdown and glucose uptake.Its intracellular action is partly mediated by cAMP and the cAMP-dependent protein kinase 44 and partly by increased Ca 2ϩ transients. 65The stimulation of glycolysis by insulin results from a control at different levels, 28 mainly a stimulation of glucose transport 66,67 and of PFK-1. 68Chronic administration of thyroid hormones also stimulates glucose transport and glycolysis. 69Inversely, in hypothyroid rats, both the expression of glucose transporters and the activity of PFK-1 are decreased. 70,71Acetylcholine may downregulate glucose utilization by increasing the concentration of cGMP (see below).

Cardiac Work
Tight coupling between cardiac work, coronary flow, and substrate oxidation is a central feature of cardiac physiology.Increased external work in working heart models modifies glucose uptake in parallel 72,73 through a recruitment of glucose transporters to the plasma membrane. 67,74The positive inotropic action of epinephrine also results in increased heart work and a marked acceleration of glucose uptake and oxidation. 36,44In both cases, the inciting stimulus of increased transport and oxidation seems to be an increase in Ca 2ϩ concentration.The increased heart work brought by systemic hypertension results in an enzymatic shift favoring the oxidation of glucose over fatty acids, 4 even in the absence of hypertrophy.

Glucose Metabolism in the Ischemic and Reperfused Heart
Glucose assumes a central role for energy production in the ischemic heart, when lack of oxygen induces a shift to anaerobic metabolism with rapid stimulation of glucose uptake, glycogenolysis, and glycolytic flux. 75,76The relative contribution of glucose to energy production is highly dependent on the severity of ischemia.In moderate ischemia (reduction of coronary flow by 75%), glucose uptake remains unchanged, while glucose extraction increases and metabolism of glucose is directed from oxidation to lactate production. 77In severe ischemia, myocardial glucose extraction is inversely related to coronary flow, 78 until the degree of ischemia becomes so severe that glycolysis is inhibited by the accumulation of its products. 793][84][85][86] The stimulation of glucose uptake by moderate ischemia is additive to that induced by insulin. 87These interventions promote glucose uptake to meet the increased demand for glucose moieties as an energy source.These conditions also stimulate glycogen synthesis. 81,88he controversy over whether the effects of glucose during ischemia are beneficial or deleterious is most likely the result of the different models used to investigate glucose metabolism and the different parameters measured by the investigators.A clear distinction must be made between glucose uptake, glycolysis, proton production, and glucose oxidation, on one hand, and between the different models of ischemia, on the other hand.Two models are mainly used to investigate heart metabolism during ischemia/reperfusion, the model of no-flow ischemia and the model of low-flow ischemia.Both models are not fully representative of the situation in vivo.In the first model, the heart is usually perfused in a working mode, and coronary flow is commensurate with the work performed.With ischemia, the flow is totally interrupted, so that all the metabolic end products accumulate in the heart.In the model of low-flow ischemia, the heart is perfused at constant coronary flow.Ischemia is induced by decreasing the coronary flow to such a value that the heart cannot further sustain its contractile activity.During low-flow ischemia, residual flow thus allows for a washout of metabolic end products.In such a model, it is possible to impose longer periods of ischemia, so that the damage induced by ischemia is only partly irreversible. 80In the model of low-flow ischemia, glucose uptake and glycolysis are accelerated, and both lactate and protons may be extruded.In the model of no-flow ischemia, glucose uptake is interrupted, glycolytic flux is supported by glycogen breakdown, and metabolic end products accumulate in the cytosol, where they not only amplify ischemic injury but eventually also shut down glycolysis. 89

Glucose Uptake
The mechanisms leading to the stimulation of glucose uptake in ischemia have recently been reviewed. 906][97] In any event, the net result is an increase in the maximal velocity of glucose transport.Glucose uptake progressively and irreversibly decreases during ischemia, despite a maintained substrate supply. 80This "metabolic exhaustion" of glucose uptake happens before irreversible ischemic injury is observed in isolated heart preparations 98 and results from inhibition of glycolytic activity by the combined effect of ionic disturbances (such as accumulation of protons), the inability to extrude the products of glycolysis (such as lactate), and the damaging effects of oxygen-derived free radicals on enzymes and membrane phospholipids.Also, cGMP increases in the ischemic heart 99 because of an activation of NO synthase, 100 the product of which stimulates cGMP production.Addition of cGMP analogues or NO donors to perfused hearts decreases glucose uptake and glycolytic flux. 101Thus, cGMP probably downregulates glucose uptake during ischemia, as the addition of NO synthase inhibitors to ischemic heart stimulates glucose metabolism and improves the resistance against ischemia. 83

Glycolytic Flux
Stimulation of glucose transport by ischemia is coupled to accelerated glycolytic flux.Such acceleration is explained by a reversal of Pasteur's effect, which is the inhibition of glycolysis by ATP.The acceleration of glycolytic flux is attributed to an activation of PFK-1 by both an increase of AMP, an activator of PFK-1, and a decrease of ATP, an inhibitor of the enzyme.The change in the ratio of these 2 nucleotides constitutes the mechanism of PFK-1 activation by ischemia, 102 since no change of fructose 2,6-diphosphate and citrate concentration is observed in this condition. 42Stimulation of glycolytic flux may also be due to a translocation of hexokinase, but this possibility has not yet been investigated.In no-flow ischemic conditions, however, the overall glycolytic flux may be limited by GAPDH, through an inhibition by the accumulation of lactate and protons, although no allosteric control of GAPDH by lactate has been found in a purified enzyme preparation. 45Glycolysis during ischemia seems particularly important in providing a residual production of ATP.Such production sustains the activity of ATPrequiring enzymes, mainly the sarcolemmal Na ϩ ,K ϩ -ATPase 103,104 and the sarcoendoplasmic Ca 2ϩ -ATPase.

Glycogen Metabolism
Glycogen breakdown during ischemia and the stimulation of glycogen phosphorylase by cAMP are long recognized but still incompletely understood.Several studies have postulated a "toxic" effect of glycogen breakdown in ischemic heart that is due to an accumulation of protons and lactate and have suggested the beneficial consequences of depleting the glycogen stores before an ischemic episode. 796][107][108][109] The absolute amount of glucose moieties arising from glycogen is not negligible at the onset of ischemia.In isolated perfused hearts subjected to low-flow ischemia, glycogen breakdown provides, during the first 15 minutes, about 60 mol glucose equivalents per gram dry weight, whereas during the same period, glucose uptake offers about 35 mol glucose per gram. 83In the same model, ischemic contracture begins when glycogen breakdown stops and, concomitantly, the rate of glucose uptake decreases.Enhanced utilization of extracellular glucose during ischemia does not increase the absolute rate of glycolytic flux but prevents the participation of glycogen stores to this flux, thereby limiting ischemic damage and contracture. 110These data indicate that cellular homeostasis in the ischemic heart is better preserved as long as glycogen is present and available for energy production. 111The exact mechanism by which glycogen protects the ischemic heart remains to be determined.
Another intriguing characteristic of glycogen metabolism in ischemic heart disease is the accumulation of glycogen in hibernating heart.Hibernating myocardium represents a chronically dysfunctional myocardium that has most likely been subjected to repetitive episodes of ischemia but is still capable of improving contractile function after reperfusion. 112o prevent irreversible tissue damage, the myocardium adapts the ventricular performance to the reduction of oxygen delivery.3][114] Hibernating myocardium is also characterized at PET by an increased signal of FDG, 115 corresponding to glycogen accumulation in the same regions. 116The increased FDG signal in hibernating myocardium could thus be related to a stimulation of glucose uptake for glycogen synthesis, although this remains to be demonstrated.Interestingly, the accumulation of glycogen and other morphological alterations seen in hibernating tissue are also found in unloaded myocardium and in fetal heart, 117,118 suggesting that hibernation may induce a reliance on glucose for energy provision similar to that observed in fetal heart.

Glycogen and Ischemic Preconditioning
Although the exact mechanism of preconditioning is most probably multifactorial, many studies have demonstrated an attenuation of glycolytic activity in preconditioned hearts.Preconditioning decreases glycogen breakdown as well as the accumulation of hexose 6-phosphates and lactate during no-flow ischemia. 119,120Because the duration of protection by preconditioning is also related to the time course of postischemic glycogen recovery, 121 the data, when taken together, show that protection by ischemic preconditioning reduces glycogen breakdown, therefore attenuating the accumulation of metabolic end products and the development of intracellular acidosis.The slower decline of both pH i and highenergy phosphates in preconditioned hearts during no-flow ischemia 122 is in agreement with this hypothesis.Most of the preconditioning protocols are performed on models of noflow ischemia; this further illustrates the importance of limiting the accumulation of glycolytic end products in the absence of residual coronary flow.The controversies about preconditioning may in part result from the variety of the models used and parameters measured.Because of the incomplete understanding of the mechanisms underlying ischemic preconditioning, it is quite impossible to gauge the relative importance of glucose metabolism in this condition.

Glucose Metabolism at Reperfusion
Both severity and duration of ischemia determine not only the extent of the metabolic and ionic derangements but also the return of function at reperfusion.The biochemical features of the postischemic heart are both similar and different from those of the ischemic heart.As for the ischemic heart, many uncertainties exist about the role of glucose as substrate during reperfusion.Again, such uncertainties may result from the different experimental models.The 2 models described above for the ischemic heart (no-flow ischemia and low-flow ischemia) are also those used to investigate the effects of reperfusion.In the model of no-flow ischemia, the ischemic episode is relatively short (Յ30 minutes), and the functional recovery at reperfusion is mainly determined by both the extent of accumulation of metabolic end products during ischemia and the substrate availability at reperfusion.In the model of low-flow ischemia, the ischemic damage is partly irreversible because of the longer episode of ischemia (usually Ն1 hour).The functional recovery at reperfusion is thus mainly determined by the extent of irreversible ischemic damage.8][129] When glycolysis is stimulated in reperfused myocardium, the cytosolic accumulation of Ca 2ϩ decreases. 128Because pharmacological interventions that prevent Ca 2ϩ accumulation in reperfused myocardium also decrease the severity of stunning, 130 it is reasonable to assume that ATP produced from glycolysis is used preferentially to support the activity of ion pumps.The efficiency of this ionic homeostasis is further improved by stimulating the PDC, 131 which reduces the accumulation of protons brought by glycolysis during ischemia.The breakdown of ATP produced from glycolysis induces a net production of protons that are consumed by the PDC.When glycolysis is not coupled to glucose oxidation, the resulting accumulation of protons stimulates the Na ϩ -H ϩ exchanger at reperfusion. 132As a result of the accumulation of Na ϩ , the Na ϩ -Ca 2ϩ exchanger is stimulated, eventually leading to Ca 2ϩ overload and reperfusion injury. 133By activating the PDC, such accumulation can be limited, and functional recovery is improved. 89Paradoxically, fatty acid oxidation is favored at reperfusion by a decrease of malonyl-CoA, thus relieving the inhibition of CPT-1. 134The decrease of malonyl-CoA results from the inhibition of ACC by a specific AMPdependent protein kinase activated by the AMP accumulation during ischemia. 134,135The beneficial effect of pyruvate at reperfusion 136 and the fact that the utilization of fatty acids instead of glucose strongly impairs the efficiency of the reperfused heart 129,137 suggest that the anaplerotic pathway is also stimulated at reperfusion.Finally, glucose at reperfusion is also required to rebuild glycogen.The best protection to the reperfused heart should be brought by a combination of stimulated glycolytic flux, activated PDC, increased glycogen storage, and anaplerosis of the Krebs cycle.This hypothesis has yet to be tested.

Glucose and Insulin as Substrates for Postischemic Heart
Substrate metabolism and contractile function are inseparable features of normal cardiac physiology.Reperfusion of ischemic myocardium is accompanied by a separation of substrate oxidation and contractile function.Prominent among the derangements responsible for functional impairment of postischemic myocardium is cellular Ca 2ϩ overload, and ATP derived from glycolysis appears to play an important role for the restoration of Ca 2ϩ homeostasis.The effects of glucose and insulin on restoration of contractile function are not entirely surprising in light of earlier clinical and experimental findings.After the effects of glucose and insulin on the ECGs of acutely ischemic dog hearts had been determined, a clinical role for GIK as a therapeutic agent was proposed in the 1960s. 138The rationale was that such a "polarizing treatment" reverses loss of intracellular K ϩ during acute ischemia.
Although the exact mechanisms for the effects of glucose and insulin in the ischemic myocardium are not known, it seems reasonable to assume that they enhance membrane stability. 104,138Shortly after, it was also observed that GIK decreases the infarct size after coronary artery ligation in dogs, lessens ultrastructural damage, and improves global contractile function of the heart. 139The infusion of GIK was shown to reduce the frequency and duration of ventricular arrhythmias and to improve the survival of patients after myocardial infarction. 140,141Similarly, beneficial effects on ejection fraction and survival were observed when GIK was administered in conjunction with a thrombolytic agent 142 or when GIK was given to patients with myocardial infarction and non-insulindependent diabetes mellitus. 143Most recently, a meta-analysis of all placebo-controlled trials of GIK treatment in acute myocardial infarction has shown an overall mortality reduction of 28%. 144A large prospective, randomized study of GIK as an adjunctive therapy to thrombolysis and/or restoration of blood flow in acute myocardial infarction has not yet been undertaken, probably for the following reasons.First, it was pointed out that the phosphorylation of glucose in glucose 6-phosphate actually uses ATP and draws on an already limited supply of the high-energy phosphates. 79Second, it was suggested that depletion of glycogen before ischemia reduces lactate production and improves contractile function with reperfusion. 79Third, in the postischemic myocardium, there is an imbalance between glycolysis on the one hand and glucose oxidation on the other. 131It has been argued that postischemic contractile dysfunction is caused by impaired glucose oxidation and cytosolic proton accumulation, and agents that enhanced glucose oxidation in the postischemic heart also seem to improve contractile function. 89Although this line of reasoning seems of compelling logic, glycolysis is also an adaptive emergency mechanism that can prevent deleterious myocyte deenergization. 127,145Thus, the use of metabolic support during both ischemia and reperfusion should complement other pharmacological interventions aimed at the restoration of normal pump function of the myocardium.Moreover, the different experimental data summarized in the previous section have shown that fatty acid metabolism is stimulated at reperfusion.This may be harmful for the heart, because it decreases functional performance and alters membrane stability. 137One of the beneficial effects of the GIK solution is the reduction of circulating free fatty acids.We have proposed that such treatment also promotes glucose oxidation, thereby limiting proton accumulation by replenishing the tricarboxylate cycle. 146he short-term infusion of GIK (up to 48 hours) has been used very effectively in patients with refractory left ventricular failure after hypothermic ischemic arrest of the heart for revascularization surgery. 147,148In these patients, the adminis-tration of GIK (a solution of 50% D-glucose containing 80 U of regular insulin and 100 mEq KCl) lowered the plasma concentration of free fatty acids, decreased systemic vascular resistance, raised the cardiac index, and increased urine output.The need for inotropic drugs, the time on the intra-aortic balloon pump, and the stay in the intensive care unit were all significantly reduced.Most important, there was a significant decrease in both short-term and long-term mortality in patients receiving GIK.These results have recently been corroborated in a larger (but nonrandomized) group of 322 patients treated at the Texas Heart Institute (Houston, Tex) and in a smaller (but randomized) study at Boston University (Boston, Mass). 149,150he rationale for the use of glucose and insulin as therapeutic agents is based on the considerations described in the first part of this review.In the ischemic heart, a protection against ischemic damage can be afforded as long as ATP is produced and protons are eliminated.The GIK solutions increase glucose uptake in the ischemic heart and probably allow for a higher rate of ATP production from glycolysis.Such ATP production inhibits ATP-dependent K ϩ channels of the plasma membrane and prevents changes of membrane potential that could lead to severe arrhythmias. 151Glycogen synthesis is also stimulated by increasing the production of glucose 6-phosphate, leading to a "glycogen loading" similar to that described above in isolated heart preparations. 146everal clinical reports stress the importance of preoperative glycogen loading for improvement of myocardial protection during cold cardioplegia and reperfusion. 152

Unresolved Issues
Many issues of glucose metabolism in the heart remain unresolved, especially with respect to the heart in vivo.Examples include the exact triggering mechanism inducing increased glucose extraction at the onset of ischemia.Although many effectors (ATP, phosphocreatine, Ca 2ϩ , AMP, and glucose 6-phosphate) have been implied, none of them seems to be the exact mechanism.Also, we have described above the ionic imbalance occurring during ischemia/reperfusion, but the real contribution of glycolysis in the production of protons remains to be measured.Experiments using NMR spectroscopy have provided tantalizing glimpses at changes in protons and Na ϩ and Ca 2ϩ concentrations but yielded no quantitative measurements on the source and fate of these ions.If proton overload induces an accumulation of Na ϩ , then a stimulation of the Na ϩ ,K ϩ -ATPase during ischemia/reperfusion should prevent Ca 2ϩ accumulation.The inhibition of GAPDH by protons and/or lactate is still controversial, because no clear conclusion could be made from experiments using purified enzyme preparations. 45The regulation of glucose transporters also remains largely unknown.Besides their recruitment to the plasma membrane, glucose transporters could also be regulated by covalent modifications, such as phosphorylation or binding of regulatory proteins.Moreover, their mechanism of trafficking between intracellular stores and plasma membrane is largely unknown.Another topic awaiting further resolution is the compartmentation of ATP.Because ATP is used for many purposes in the heart (eg, contraction, Ca 2ϩ reuptake and other ionic pumps, protein phosphorylation, and glycolysis), it is possible that a real compartmentation of high-energy phosphates exists.Also of interest is the increasing awareness of the importance of phosphorylation signaling pathways, which are intimately intertwined with enzyme regulation.Proteins such as mitogen-activated protein kinases, AMP-dependent protein kinase, cAMP-dependent protein kinases, cGMP-dependent protein kinases, protein kinase C, Jun NH 2 -terminal kinase, and many others are now familiar terms, and the future will tell us more about the role of phosphoprotein phosphatases.Of growing interest is the study of intercellular communication, mainly that between the cardiomyocyte and the endothelial cell.Metabolic effects of many intercellular mediators, such as NO, cAMP, cGMP, adenosine, endothelin-1, bradykinin, and interleukins, are now under investigation.Last, the tools of molecular biology will help to define the long-term regulation of metabolism at the transcriptional level.It is very likely that clinical situations such as hibernation, heart failure, hypertrophy, chronic ischemic heart disease, and cardiomyopathies induce a shift in the genetic expression of metabolic enzymes, contractile proteins, and oncogenes.A better understanding of these alterations may help to prevent them and could provide potential targets for gene therapy.

Figure 3 .
Figure 3. Regulation of the PDC.PDC is inhibited by PDH kinase and stimulated by PDH phosphatase.PDH kinase is regulated by acetyl-CoA and NADH.PDH phosphatase is activated by Ca 2ϩ and Mg 2ϩ .

Figure 4 .
Figure 4. Regulation of fatty acid oxidation by glucose and lactate.CPT-1 is inhibited by malonyl-CoA, which is produced from acetyl-CoA by ACC.